Pentoxifylline is known to have major effects on cell membrane function in mammalian cells, including human leukocytes. The protective effects of this agent in animal models of infection and inflammation may be due to alterations in phagocyte (neutrophil and macrophage) function. However, the exact mechanism of action of pentoxifylline is unknown. In this study, we evaluated the effect of the drug on several membrane-associated activities in human polymorphonuclear neutrophils and investigated possible mechanisms for the observed changes in neutrophil function. Pentoxifylline inhibited ingestion of microbial particles (Staphylococcus aureus and zymosan); decreased superoxide generation activated by zymosan, formyl-methionyl-leucyl-phenylalanine, and concanavalin A (but not phorbol myristate acetate); and decreased uptake (transport) of adenosine stimulated by formyl-methionyl-leucyl-phenylalanine and zymosan. In contrast, pentoxifyiline actually increased clindamycin uptake in zymosan-stimulated polymorphonuclear neutrophils. However, pentoxifyHline had no effect on uptake of adenosine or clindamycin in unstimulated neutrophils. In comparison with known inhibitors of nucleoside transport (nitrobenzylthioinosine and dipyridamole), the results suggested that pentoxifylline does not bind to membrane nucleoside transport receptors. At concentrations which inhibit neutrophil function, pentoxifylline activity is not mediated through external membrane nucleoside regulatory sites. Thus, pentoxifylline affects the activation signal chain at a point beyond the membrane receptors. Whatever its precise mechanism of action, pentoxifylline has a striking modulatory effect on cell membraneassociated responses in stimulated leukocytes and may prove useful for control of injurious inflammatory states.
Pentoxifylline is a methylxanthine derivative known to alter mammalian cell membranes (13, 27, 34, 36) . This drug is used clinically for treatment of certain vascular insufficiency syndromes because of its ability to lower blood viscosity and increase microcirculatory flow (30, 39) . The mode of action of pentoxifylline in this setting may be to increase erythrocyte flexibility (deformability). Recently the drug has been shown to have major effects on leukocyte membrane function (2, 14, 19, 24, 26, 34, 36, 42, 43) . Thus, pentoxifylline enhances chemotaxis, increases cell deformability, decreases adherence, and blocks the action of inflammatory cytokines on neutrophils. Associated cellular changes include an increase in cyclic AMP levels, decreased free intracellular calcium, and altered phosphatidyl nucleotide metabolism, but the relationship of these findings to the mechanism of action of pentoxifylline is unknown. In addition, there appears to be a protective action of the drug in animal models of bacterial infection and inflammation, perhaps due to alterations in leukocyte (neutrophil and macrophage) function (3, 7, 21, 24, 33, 43, (45) (46) (47) .
Thus, the evidence indicates that pentoxifylline has a profound influence on leukocyte cell membrane function and structure. In this study, we examined the effects of the drug on several membrane-associated activities in human polymorphonuclear neutrophils (PMN). Specifically, we observed the influence of pentoxifylline on ingestion of microbial particles, oxidative burst activity, and antibiotic and nucleoside uptake (membrane transport) in PMN. We also evaluated possible mechanisms, binding of external mem- 82.1 ± 6.1 (5), P = 0.029 106.5 ± 9.5 (5), P = 0.38 114.1 ± 4.9 (5), P = 0.03 10 72.3 ± 6.5 (8) , P = 0.003 98.1 ± 6.0 (8) , P = 0.59 101.7 ± 4.8 (8) , P = 0.57 15 73.5 ± 5.8 (9) , P = 0.001 89.9 ± 4.9 (9) , P = 0.02 89.7 ± 5.2 (7), P = 0.07 20 82.0 ± 3.7 (10), P = 0.0006 92.9 ± 7.0 (10), P = 0.26 94.3 ± 4.1 (10), P = 0. 15 30 99.5 ± 7.3 (10) , P = 0.77 103.8 ± 7.8 (10) , P = 0.5 116.0 ± 6.7 (10), P = 0.003 a Data are means + standard errors of the means. The number of experiments is shown in parentheses. P values reflect differences between control and pentoxifylline groups.
Phagocytosis of microbial particles by human PMN. (i) S.
aureus. PMN (107) were preincubated with or without pentoxifylline for 30 min in tubes containing 0.9 ml of HBSS-0.1% gelatin. Radiolabeled, opsonized S. aureus (108 bacteria in 0.1 ml of HBSS) was added to each tube. The tubes were then incubated at 37°C in 95% air-5% CO2 with rotation (Multi-Purpose Rotator; Scientific Industries Inc., Springfield, Mass). After an ingestion period of 5 to 30 min, lysostaphin (10 U/ml) was added to the assay tubes for 10 min to kill extraphagocytic S. aureus. PMN were recovered by centrifugation and washed twice in HBSS. The washed pellet (after cell lysis in distilled water) was appropriately diluted and used for bacterial enumeration and radioactive counting. Specimens were plated on tryptic soy agar for enumeration of viable bacteria or processed for determination of radioactivity in a Beckman LS-3801 liquid scintillation counter. Radioactive counts were expressed as disintegrations per minute.
Calculations of bacterial ingestion at each time point were performed as previously described (16, 18) . Phagocytosis of S. aureus by PMN was determined in the following manner: number of ingested organisms = (number of viable organisms in bacterial inoculuml3H counts in bacterial inoculum)
x intracellular 3H counts.
The consequences of PMN exposure to pentoxifylline for ingestion of S. aureus was determined and compared with control values as follows: percent control phagocytosis = (intraphagocytic bacteria-control/intraphagocytic bacteriapentoxifylline) x 100.
(ii) Zymosan. PMN (107 in 1 ml of HBSS) were preincubated with or without pentoxifylline as described above. Opsonized zymosan particles were added to the tubes, followed by incubation with rotation at 37°C for 30 min. Cell pellets were collected by centrifugation, washed, and smeared on glass slides. The slides were fixed with methanol and stained with methylene blue.
On each slide, 500 consecutive nonaggregated PMN were counted in a blinded fashion to determine the percentage of cells which phagocytized zymosan and the total number of particles ingested. The phagocytic index (number of ingested particles/number of cells) was also calculated for each experiment.
Influence of pentoxifylline and nucleosides on PMN superoxide production. Superoxide generation by human PMN was determined as superoxide dismutase-inhibitable reduction of ferricytochrome c (8, 16, 23) . PMN (2 x 106/3 ml) in HBSS containing 100 ,uM ferricytochrome c were preincubated with or without pentoxifylline, adenosine, or a nucleoside inhibitor for 15 min at 37°C. Cytochalasin b (5 ,ug/ml) and either a stimulating agent (zymosan, FMLP, PMA, or ConA) or control medium was then added to the incubation tubes. Duplicate samples contained superoxide dismutase (50 ,ug/ml). After incubation for 30 min, the cells were removed by centrifugation at 4°C. The optical densities of the supernatants were determined at 550 nm in a spectrophotometer (Carey 219). The difference between duplicate samples with and without superoxide dismutase was calculated, and reduced cytochrome c was quantitated by using the equation E550 = 2.1 x 104 M-1 cm-1.
Antibiotic and nucleoside uptake by human PMN. Uptake of radiolabeled clindamycin and adenosine by PMN was determined by a velocity gradient centrifugation technique which we have previously described in detail (17, 22, 31, 40 10-' M (clindamycin, 10 ,ug/ml; adenosine, 7 ,ug/ml). In some experiments, pentoxifylline was added to the PMN suspension and preincubated for 20 min before addition of radiolabeled clindamycin or adenosine. At specified times, antibiotic or nucleoside uptake was determined by velocity gradient centifugation in a microcentrifuge. Clindamycin and adenosine uptake was expressed as the ratio of the cellular concentration of antibiotic to the extracellular concentration (CIE).
Assay of phagocyte cytoplasmic enzyme release. Release of lactic dehydrogenase (LDH), a cytoplasmic enzyme, was monitored as an indicator of cellular injury. PMN in HBSS (107/ml) were preincubated with or without pentoxifylline for 15 min, followed by addition of the stimulating agent (FMLP or zymosan). After additional incubation with rotation for 20 min at 37°C, the cells were recovered by centrifugation, resuspended, and lysed in 0.2% Triton X-100. Enzyme activity was determined in cell pellets, supernatants, and whole-cell suspensions (without centrifugation and after Triton X-100 disruption). LDH was assayed by measuring the increase in A340 resulting from reduction of NAD to form NADH (1).
RESULTS
Characteristics of the cell population. The granulocyte population was -97% neutrophils. Since .90% of these cells were mature polymorphonuclear neutrophilic leukocytes, the cells will be referred to as PMN. Cell viability was >95%, as judged by trypan blue exclusion. (Table 3 ). In contrast to pentoxifylline, the inhibitory activity of adenosine was nearly maximal at -1 x 10-' to 2.5 x 10-5 M and increased only slightly with higher concentrations. Furthermore, adenosine markedly inhibited superoxide production by PMN stimulated with soluble activators (FMLP and ConA) but had less effect on microbial particle-induced production of superoxide. As noted above, pentoxifylline had a concentration-dependent inhibitory activity which was virtually identical for PMN exposed to FMLP, ConA, or zymosan.
Methylxanthines are antagonists at external membrane nucleoside-binding sites and may block the influence of adenosine on cellular function. Therefore, we studied the effects of adding both pentoxifylline and adenosine to the neutrophil incubation mixture. Not only did pentoxifylline fail to block adenosine activity, but this combination of agents actually had an additive effect (greater inhibition than either substance alone) on FMLP-and zymosan-stimulated PMN (Table 4) . As we previously demonstrated (Hand et al., submitted), NBTI and dipyridamole, which bind to cell membrane nucleoside transport receptors and thereby inhibit nucleoside transport (29, 48) , also inhibited PMN superoxide production stimulated by FMLP. It is of note that the inhibitory effects of pentoxifylline and NBTI on FMLP-induced superoxide production were additive (Table  4) .
Adenosine deaminase blocked the inhibitory effects of adenosine on FMLP-and zymosan-stimulated superoxide production. However, addition of adenosine deaminase caused no alteration in the inhibition of superoxide generation due to pentoxifylline or NBTI.
We considered the possibility that pentoxifylline might directly interfere with reduction of cytochrome c rather than alter PMN production of superoxide. However, pentoxifylline had no effect on the reduction of cytochrome c by superoxide generated in a cell-free system (hypoxanthinexanthine oxidase).
Antibiotic uptake. As we have previously shown (17, 31, 40) , uptake of clindamycin by human PMN was striking (CIE = 10 to 11) ( (4) 11.1 ± 1.8 (7) 10.7 ± 1.5 (7) 10.0 ± 1.9 (5) Pentoxifylline 8.6 ± 0.9 (2) 11.7 ± 2.2 (5), P = 0.18 11.2 ± 1.9 (5), P = 0.28 11.5 ± 3.3 (3), P = 0.08 Zymosan 9.6 ± 1.8 (4), P = 0.46b 13.6 ± 1.6 (7), P = 0.003 15.1 ± 1.7 (7), P = 0.002 16.6 ± 2.8 (5), P = 0.012
Zymosan + pen-11.3 ± 1.2 (4), P = 0.06c 16.3 ± 1.8 (7), P = 0.014
18.4 ± 2.1 (7), P = 0.07 20.1 ± 3.6 (5), P = 0.057 toxifylline Adenosine Control 0.2 ± 0.1 (9) 0.7 ± 0.1 (11) 1.2 ± 0.1 (16) 1.9 ± 0.2 (13) Pentoxifylline 0.5 ± 0.2 (9), P = 0.09b 0.9 ± 0.2 (11), P = 0.26 1.3 ± 0.2 (16), P = 0.32 2.0 ± 0.4 (13), P = 0.50 Zymosan 0.9 ± 0.2 (9), P = 0.0002b 1.7 ± 0.1 (11), P = 0.00002 2.4 ± 0.2 (16), P = 0.00001 3.2 ± 0.3 (13), P = 0.00001 Zymosan + pen-0.7 ± 0.2 (9), P = 0.04C (41) . Perhaps as a consequence of this role in modulating leukocyte function, pentoxifylline proved to be protective in animal models of bacterial infection and inflammation (3, 7, 21, 24, 33, 43, (45) (46) (47) . The mechanism(s) for the effects of pentoxifylline on leukocyte function has not been established, but associated cellular changes have included an increase in cyclic AMP levels, altered phosphatidyl nucleotide metabolism, and decreased intracellular calcium.
In this study, we examined the effects of pentoxifylline on specific membrane-associated activities in human PMN. The drug suppressed several stimulus-induced cell membrane functions in neutrophils. Pentoxifylline inhibited ingestion of microbial particles (S. aureus and zymosan) by human PMN. Furthermore, pentoxifylline exhibited a marked inhibitory effect on superoxide generation in PMN activated by soluble substances (FMLP and ConA) or microbial particles (zymosan). Pentoxifylline had little influence on superoxide production stimulated by PMA, which bypasses membrane receptor-related mechanisms of activation and directly stimulates protein kinase C (6). Pentoxifylline also decreased uptake (transport) of adenosine in zymosan-and FMLPstimulated (but not control) PMN. Thus, pentoxifylline inhibited three cell membrane-associated functions (phagocytosis, respiratory burst activity, and nucleoside transport) in stimulated human PMN.
The evidence clearly indicates that pentoxifylline has a profound effect on neutrophil cell membrane function and structure. Although the exact means by which this drug interacts with the cell membrane is not known, other methylxanthines produce recognized alterations in cellular function (11, 12, 20) . Methylxanthines inhibit phosphodiesterase activity, which could account for the observed elevation in cellular cyclic AMP levels. This sequence might lead to the biological changes observed after administration of these drugs. However, other findings have suggested that phosphodiesterease inhibition occurs only at high concentrations for many methylxanthine drugs (11, 12, 20) .
The modulation of cellular functions by pentoxifylline is similar to the changes caused by nucleosides. Adenosine plays a role in regulation of activation for many types of cells (12, 25, 35) . For example, this nucleoside inhibits respiratory burst activity (generation of superoxide and hydrogen peroxide) in stimulated human PMN (9, 10; Hand et al., submitted) . This regulatory activity of nucleosides appears to be mediated through external cell membrane receptors which are either stimulatory (A2) or inhibitory (A1) (12, 25) for guanine nucleotide regulatory (G or N) protein-adenylate cyclase activity (35, 38) . Furthermore, specific receptor-G protein complexes may also regulate phospholipase C activity, with an effect on polyphosphoinositide breakdown and intracellular Ca2+ mobilization, thereby altering the functions of the respiratory burst enzyme and other cellular activities (37) . Adenosine inhibition of FMLP-stimulated superoxide production in PMN is probably mediated by binding to A2 receptors (9, 10) .
Methylxanthines are inhibitors of nucleoside receptor binding (5, 11, 12, 20) and nucleoside transport (29, 48) , and it has been shown that these agents block adenosine activity mediated by regulatory receptors. Therefore, the possibility that pentoxifylline alters PMN function by binding to nucleoside-regulatory membrane receptors has been considered. Indeed, certain findings in our study are compatible with the concept that the effects of pentoxifylline on neutrophil function are mediated through nucleoside cell membrane receptor pathways. Both adenosine (9, 10, 32; Hand et al., submitted) and pentoxifylline inhibit stimulated respiratory burst activity and promote chemotaxis in neutrophils. We also found that pentoxifylline is an effective inhibitor of stimulated adenosine uptake in PMN. NBTI, which binds to cell membrane nucleoside transport receptors and competitively inhibits adenosine uptake (29, 48; Hand et al., submitted), produced an effect on PMN superoxide production which is similar to and additive with that of pentoxifylline.
However, there are also major differences between pentoxifylline and adenosine in their effects on PMN function. Pentoxifylline (at concentrations greater than 10' M) had a progressive, concentration-dependent inhibitory effect on stimulated superoxide production in PMN. In contrast, the activity of adenosine was essentially maximal at 1 x 10-5 to 2.5 x 1O' M (presumably because of saturation of external membrane receptors). Adenosine was a potent inhibitor of PMN superoxide production induced by soluble mediators (FMLP and ConA) but had less effect on microbial particleinduced prduction of superoxide. This may be related to the recent finding that microbial particle (opsonized zymosan) activation of the neutrophil respiratory burst differs from activation by certain other stimulating agents (28, 44) . In contrast to adenosine, pentoxifylline had concentrationdependent inhibitory activity which was similar for cells exposed to FMLP, ConA, or zymosan.
Although pentoxifylline is a methylxanthine derivative, the drug failed to block the inhibitory activity of adenosine on PMN superoxide production. Indeed, pentoxifylline and adenosine were additive in their modulation of superoxide production. This suggests that these two agents have different pathways of action. Of considerable interest is the fact that NBTI and dipyridamole, but not pentoxifylline, decrease adenosine uptake (transport) in unstimulated neutrophils, implying that pentoxifylline does not bind to nucleoside transport receptors. We have shown that clindamycin enters PMN and macrophages by active membrane transport, at least in part via the nucleoside transport system (15, 40) . Pentoxifylline, but not the nucleoside derivative NBTI, actually increased clindamycin uptake in zymosan-stimulated PMN. This also indicates that pentoxifylline does not bind to nucleoside transport receptors.
These findings make it highly unlikely that the modulatory effects of pentoxifylline on neutrophil function are mediated through external membrane nucleoside regulatory or transport receptors, either directly by receptor binding or indirectly by increased extracellular adenosine (due to inhibition of adenosine transport by pentoxifylline). This latter possibility is excluded by our finding that adenosine deaminase, which blocks the effect of adenosine on superoxide production, failed to alter suppression of superoxide generation due to pentoxifylline.
Thus, the findings suggest that the modulatory effects of pentoxifylline on neutrophil function are not caused by binding of external cell membrane receptors. The exact site of interaction in the activation signal chain is not known. As noted above, pentoxifylline has little effect on PMA-stimulated superoxide production mediated through protein kinase C (6) . Therefore, pentoxifylline presumably affects another pathway of activation. Changes in cellular cyclic nucleotide levels or phospholipase C activity (which affects polyphosphoinositide metabolism and intracellular calcium mobilization) are potential sites of action. It 
